This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Top Analyst Reports for UnitedHealth, Citigroup & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Citigroup (C) and Honeywell (HON).
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
Why Amgen (AMGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
by Zacks Equity Research
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
by Zacks Equity Research
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
by Zacks Equity Research
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More
by Kalyan Nandy
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Coca-Cola (KO) and Amgen (AMGN).
Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
by Zacks Equity Research
Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.
Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
by Zacks Equity Research
Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.
Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $184.28 in the latest trading session, marking a +0.14% move from the prior day.
Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View
by Zacks Equity Research
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
by Zacks Equity Research
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $184.08, moving +0.72% from the previous trading session.
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara